Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.
Pingping Jiang, Min Deng, Qian Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared the anesthetic efficacy and safety of remimazolam versus propofol in 82 liver cancer patients undergoing percutaneous radiofrequency ablation. The study found that remimazolam provided better hemodynamic stability and respiratory safety, with a significant reduction in hypotension requiring vasopressors (22.0% vs 46.3%, p = 0.015) and shorter recovery time (9.65 ± 1.81 vs 15.05 ± 3.58 min, p < 0.001).
Key findings
- Remimazolam resulted in higher mean arterial pressure at specific time points compared to propofol.
- Lower incidence of apnea was observed in the remimazolam group (17.1% vs 36.6%, p = 0.038).
- Remimazolam led to less hypotension requiring vasopressors (22.0% vs 46.3%, p = 0.015).
- Recovery time was significantly shorter with remimazolam (9.65 ± 1.81 vs 15.05 ± 3.58 min, p < 0.001).
Why it matters
The findings suggest that remimazolam may enhance hemodynamic stability and respiratory safety in liver cancer patients undergoing anesthesia, which is crucial given their often complex medical profiles. This could influence anesthetic choices in similar clinical scenarios.